Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic review
DOI:
https://doi.org/10.13037/ras.vol15n52.4439Keywords:
Hyperlipoproteinemia type II, LDL lipoproteins, Myocardial infarction, PCSK9Abstract
Introduction: The hypercholesterolemia can lead to conditions such as acute myocardial infarction (AMI). However, cholesterol elevation is not always caused by poor diet habits and lifestyle; groups such as familial hypercholesterolemia (HF) have serum values increased by genetic alterations, and traditional dyslipidemic medications are not effective enough for these peoples. Objective: To compile and discuss the results obtained by the current literature that focuses on the evolocumab monoclonal antibody to decrease PCSK9 levels. Materials and methods: Systematic review of the results of tests done with humans over 19 years of age, published in the last 5 years in the English language, using the PubMed database. Results: 135 articles were found, and nine studies were selected by exclusion criteria. Discussion: Results demonstrated that the pharmacological power of the evolocumab antibody has a remarkable value compared to the usual therapies and placebo for patients who did not show great response to current therapies. Conclusion: This is a very recent study, which requires further research to show possible adverse reactions and interactions with other drugs. However, so far it has demonstrated a great advantage for future treatments because it occupies a place not previously filled by traditional pharmacology.
Downloads
References
1. Marte AP, Santos RD. Bases fisiopatológicas da dislipidemia e hipertensão arterial. Rev Bras Hipertens. 2007;14(4):252-7.
2. Duarte M, Moresco RN, Bem AFD. Metodologia para a determinação da LDL oxidada e sua aplicação como marcador de risco cardiovascular. Rev Bras Anal Clin. 2008;40(2):101-6.
3. Perez M, José D. Complicações cirúrgicas do infarto agudo do miocárdio: uma revisão da literatura. XXVII Jornada Científica Internato; 2016 28-30 Out; Teresópolis, Rio de Janeiro, Brasil. Teresópolis: Unifeso; 2016.
4. Péres DS, Magna JM, Viana LA. Portador de hipertensão arterial: atitudes, crenças, percepções, pensamentos e práticas. Rev Saúde Públ. 2003;37(5):635-42.
5. Lopes HF, Barreto Filho JAS, Riccio GMG. Tratamento não-medicamentoso da hipertensão arterial. Rev Soc Cardiol Estado São Paulo. 2003;13(1):148-55.
6. Molinari GJDP, Moreira PCS, Conterno LO. A influência das estratégias promocionais das indústrias farmacêuticas sobre o receituário médico na Faculdade de Medicina de Marília: uma visão ética. Rev Bras Educ Med. 2005;29(2):110-8.
7. Bortolotto LA. Hipertensão arterial e insuficiência renal crônica. Rev Bras Hipertens. 2008;15(3):152-5.
8. Xavier HT, Izar MC, Faria Neto JR, Assad MH, Rocha VZ, Sposito AC, et al. V Diretriz brasileira de dislipidemias e prevenção da aterosclerose. Arq Bras Cardiol. 2013;101(4):1-20.
9. Schulz I. Tratamento das dislipidemias: como e quando indicar a combinação de medicamentos hipolipemiantes. Arq Bras Endocrinol Metab. 2006;50(2):344-59.
10. Girardi JM, Girardi FA, Peters VM. Endotélio vascular e efeitos das estatinas. HU Rev. 2006;32(1):21-5.
11. Adams-Sánchez CD, Tobón-García GJ. Monoclonal antibody therapy in Cardiology and Internal Medicine. Rev Colomb Cardiol. 2016;23(4):293-300.
12. Corral P. De volta ao básico: PCSK9 como um novo alvo para o receptor LDL. Arq Bras Cardiol. 2014;102(1):5-8.
13. Torrinha JMDQ, Fleming L. Inibidores PCSK9 [tese]. Porto: Universidade Fernando Pessoa; 2015.
14. Hopkins PN, Defesche J, Fouchier SW, Bruckert E, Luc G, Cariou B, et al. Characterization of autosomal dominant
hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal
antibody. Circ Cardiovasc Genet. 2015;8(6):823-31.
15. Pereira AC, Gagliardi ACM, Lottenberg AM, Chacra APM, Faludi AA, Sposito AC, et al. I Diretriz brasileira de hipercolesterolemia familiar (HF). Arq Bras Cardiol. 2012;99(2):1-28.
16. Pereira C, Miname M, Makdisse M, Filho RK, Santos RD. Associação das doenças arterial periférica e cardiovascular na hipercolesterolemia familiar. Arq Bras Cardiol. 2014;103(2):118-23.
17. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50(Suppl):S172-7.
18. Le Bras M, Roquilly A, Deckert V, Langhi C, Feuillet F, Sébille V, et al. Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury. Int J Clin Endocrinol Metab. 2013;98(4):732-6.
19. Souza GP, Pereira JAS, Judice WAS. Caracterização de inibidores sobre a atividade da pró-proteína convertase furina. Biochem Biotechnol Res. 2013;2(3):309-12.
20. Forti N, Salazar LA, Diament J, Giannini SD, Hirata MH, Hirata RD. Alterações genéticas e colesterolemia: recentes estudos brasileiros. Arq Bras Cardiol. 2003;80(5):565-71.
21. Botham KM, Mayes PA. Síntese, transporte e excreção do colesterol. In: Murray RK, Granner DK, Mayes PA, Rodwell VW. Harper: bioquímica. São Paulo: Atheneu; 2016. p. 266.
22. Beisiegel U, Weber W, Ihrke G, Herz, J, Stanley KK. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature. 1989;341(6238):162-4.
23. Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA. 2005;102(6):2069-74.
24. Siqueira AF, Abdalla DS, Ferreira SR. LDL: from metabolic syndrome to instability of the atherosclerotic plaque. Arq Bras Endocrinol Metabol. 2006;50(2):334-43.
25. Stryer L. Biosynthesis of membrane lipids and steroids. In: Berg JM, Timoczkp JL, Stryer L. Biochemistry. New York: Macmillan; 1996. p. 697-8.
26. Genta MLND. Farmacocinética e captação tecidual do paclitaxel associado à nanoemulsão (LDE) em pacientes com neoplasias malignas do trato genital feminino [tese]. São Paulo: Universidade de São Paulo; 2006.
27. Elguindy A, Yacoub MH. The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research.
Glob Cardiol Sci Pract. 2013;39(4):343-7.
28. Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis. 2013;228(1):18-28.
29. Cohen JC, Boerwinkle E, Mosley Jr TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264-72.
30. Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380(9858):2007-17.
31. Kohli P, Desai NR, Giugliano RP, Kim JB, Somaratne R, Huang F, et al. Design and rationale of the LAPLACETIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol. 2012;35(7):385-91.
32. Cho L, Rocco M, Colquhoun D, Sullivan D, Rosenson RS, Dent R, et al. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. Clin Cardiol. 2014;37(3):131-9.
33. Hirayama A, Honarpour N, Yoshida M, Yamashita S, Huang F, Wasserman SM, et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk. Circ J. 2014;78(5):1073-82.
34. Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Bays H. Anti-PCSK9 monotherapy for hypercholesterolemia:
the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2531-40.
35. Stein EA, Giugliano RP, Koren MJ, Raal FJ, Roth EM, Weiss R, et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J Qual Care Clin Outcomes. 2014;35(33):2249-59.
36. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS , Watts GF, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS- 2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541-8.
37. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500-9.
38. Kiyosue A, Honarpour N, Kurtz C, Xue A, Wasserman SM, Hirayama A. A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk. J Am Coll Cardiol. 2016;117(1):40-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2017 Mario Henrique Quim Ferreira, Rodrigo Metzker Pereira Ribeiro, Ana Beatriz Antunes Funes, Bruna Mohine Oliveira Faustino, Fernanda Cardin Segato, Luana Lozano Cardoso de Mattos, Thais Caroline dos Santos Carvalho, Carlos Funes Prada Filho
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Policy Proposal for Journals offering Free Delayed Access
Authors who publish in this magazine agree to the following terms:
- Authors maintain the copyright and grant the journal the right to the first publication, with the work simultaneously licensed under a Creative Commons Attribution License after publication, allowing the sharing of the work with recognition of the authorship of the work and initial publication in this journal.
- Authors are authorized to assume additional contracts separately, for non-exclusive distribution of the version of the work published in this magazine (eg, publishing in institutional repository or as a book chapter), with the acknowledgment of the authorship and initial publication in this journal.
- Authors are allowed and encouraged to publish and distribute their work online (eg in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes, as well as increase impact and citation of the published work (See The Effect of Open Access).
